Vischer advised RLF in closing agreement with Sonnet BioTherapeutics

Relief Therapeutics Holding (RLF) announces the closing of the binding Share Exchange Agreement for the acquisition by Sonnet BioTherapeutics, now a subsidiary of Sonnet BioTherapeutics Holdings (formerly known as Chanticleer Holdings) of Relief Therapeutics, a subsidiary of Relief Holding, signed August 12, 2019. As a consequence, Sonnet acquires all outstanding shares of Relief SA that becomes a wholly owned Geneva-based subsidiary of Sonnet. In counterpart, Sonnet paid to Relief Holding shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock.

Vischer advises the selling shareholder in this transaction. The team was led by partner Damien Conus (head of Geneva m&a/start-up desks).